Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from ...

Remicade (infliximab) is a prescription drug that’s used to manage certain autoimmune conditions in adults and some children. The drug is usually given as an intravenous (IV) infusion every 8 weeks.

Remicade (infliximab) is a prescription drug that’s used to treat certain autoimmune conditions, such as rheumatoid arthritis. Remicade can cause side effects that range from mild to serious. Examples ...

Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...

Please provide your email address to receive an email when new articles are posted on . While serologic protection was achieved in only a relatively low proportion of IBD patients on Remicade ...

Birmingham, UK - Although infliximab (Remicade, Centocor) was licensed for use in the treatment of ankylosing spondylitis (AS) in Europe nearly 2 years ago, in the UK there has been little experience ...

Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of ...

PHILADELPHIA, PA, October 15, 2007- Clinical data presented today at the annual meeting of the American College of Gastroenterology (ACG) show that REMICADE significantly reduces the incidence of ...

crohns disease Patients with Crohn disease were enrolled in a comparative cohort study that analyzed the outcomes of reference product infliximab vs biosimilar treatment. The effectiveness of ...